The Potential Demand for and Strategic Use of an HIV-1 Vaccine in Southern India

Vista sencilla de ítem
dc.creatorSeshadri, Shreelata Rao
dc.creatorSubramaniyam, P.
dc.creatorJha, Prabhat
dc.date2014-05-09T19:03:40Z
dc.date2014-05-09T19:03:40Z
dc.date2003-05
dc.date.accessioned2026-07-01T01:30:04Z
dc.descriptionEven a modestly effective HIV-1 vaccine would be highly useful in India and could avoid millions of deaths. How should such a vaccine be introduced? Based on evidence of adoption of other vaccines in India, current levels of spending on them and coverage of prevention programs targeting both high- and low-risk groups, Seshadri, Subramaniyam, and Jha assess the potential demand for and strategic use of an HIV-1 vaccine in the four southern Indian states of Andhra Pradesh, Karnataka, Maharashtra, and Tamil Nadu. The authors also discuss potential strategies for delivery of the vaccine, prioritization for vaccination, and the political economy of such a vaccine in India. Assuming a vaccine cost of $10 a dose and including estimated delivery costs, the total cost of vaccinating 21.6 million adolescents 11-14 years of age and 1 percent of adults would be Rs. 12.25 billion (US$ 245 million). To maintain the vaccination rate in the 11-14 year old cohort, an additional 6.77 million in that age range would have to be vaccinated each year, at a vaccine cost of Rs. 3.39 billion (US$ 67.5 million). An HIV-1 vaccine will greatly reduce HIV/AIDS in India, but it will not be a panacea. There will be a continued need for effective prevention programs to guard against behavior reversals or an imperfect vaccine. Key inputs for prevention, immunization, and treatment programs such as identification of various groups that could be immunized (vulnerable groups or general populations), strengthened surveillance, capacity building, operations research, and evaluation at local levels will continue to require intensive support.
dc.formatapplication/pdf
dc.formattext/plain
dc.identifierhttp://documents.worldbank.org/curated/en/2003/05/2378824/potential-demand-strategic-use-hiv-1-vaccine-southern-india
dc.identifierhttps://hdl.handle.net/10986/18219
dc.identifierhttps://doi.org/10.1596/1813-9450-3066
dc.identifier.urihttp://hdl.handle.net/123456789/418664
dc.languageEnglish
dc.languageen_US
dc.publisherWorld Bank, Washington, DC
dc.relationPolicy Research Working Paper;No. 3066
dc.rightsCC BY 3.0 IGO
dc.rightshttp://creativecommons.org/licenses/by/3.0/igo/
dc.subjectHIV VIRUSES
dc.subjectVACCINES
dc.subjectVACCINATION
dc.subjectHEALTH ISSUES
dc.subjectHEALTH SERVICES
dc.subjectACQUIRED IMMUNE DEFICIENCY SYNDROME VACCINES
dc.subjectPREVENTIVE MEDICINE
dc.subjectIMMUNIZATION
dc.subjectCAPACITY BUILDING
dc.subjectPUBLIC AWARENESS
dc.subjectPUBLIC HEALTH
dc.subjectFUNDING ACCESS TO EDUCATION
dc.subjectADOLESCENT
dc.subjectADOLESCENT GIRLS
dc.subjectADOLESCENTS
dc.subjectADULT POPULATION
dc.subjectADULTHOOD
dc.subjectAGED
dc.subjectAGING
dc.subjectAIDS PREVENTION
dc.subjectAIDS VACCINE
dc.subjectANTENATAL CARE
dc.subjectANTENATAL CLINIC
dc.subjectANTENATAL CLINICS
dc.subjectASYMPTOMATIC INFECTIONS
dc.subjectAWARENESS CAMPAIGNS
dc.subjectBABIES
dc.subjectBEHAVIOR CHANGE
dc.subjectBEHAVIORAL SURVEILLANCE
dc.subjectBILATERAL DONORS
dc.subjectBIRTH RATE
dc.subjectBIRTHS
dc.subjectCHILD DEVELOPMENT
dc.subjectCHILD HEALTH
dc.subjectCHILDHOOD IMMUNIZATION
dc.subjectCLINICAL TRIALS
dc.subjectCLINICS
dc.subjectCOMMERCIAL SEX
dc.subjectCOMMERCIAL SEX WORKERS
dc.subjectCONDOM DISTRIBUTION
dc.subjectCONDOM PROMOTION
dc.subjectCONDOM USE
dc.subjectCONDOMS
dc.subjectCONTRACEPTION
dc.subjectDISCRIMINATION
dc.subjectDROPOUT RATES
dc.subjectDRUG USERS
dc.subjectEARLY DETECTION
dc.subjectEFFECTIVE PREVENTION
dc.subjectEFFECTIVE VACCINES
dc.subjectENROLLMENT
dc.subjectENROLLMENT RATES
dc.subjectEPIDEMIOLOGICAL FACTORS
dc.subjectFAMILIES
dc.subjectFAMILY HEALTH
dc.subjectFATIGUE
dc.subjectFEMALE SEX WORKERS
dc.subjectGIRLS
dc.subjectGOVERNMENT CLINICS
dc.subjectHEALTH CARE
dc.subjectHEALTH FACILITIES
dc.subjectHEALTH FACILITY
dc.subjectHEALTH INTERVENTIONS
dc.subjectHEPATITIS B
dc.subjectHEPATITIS B SURFACE ANTIGEN
dc.subjectHEPATITIS B VIRUS
dc.subjectHETEROSEXUAL TRANSMISSION
dc.subjectHIGH-RISK
dc.subjectHIGH-RISK GROUPS
dc.subjectHIGH-RISK POPULATIONS
dc.subjectHIV
dc.subjectHIV IMMUNIZATION
dc.subjectHIV INFECTIONS
dc.subjectHIV PREVENTION
dc.subjectHIV PREVENTION INTERVENTIONS
dc.subjectHIV VACCINATION
dc.subjectHOSPITALS
dc.subjectHUMAN IMMUNODEFICIENCY VIRUS
dc.subjectIMMUNIZATION
dc.subjectIMMUNIZATION COVERAGE
dc.subjectIMMUNODEFICIENCY
dc.subjectINFECTION
dc.subjectINFECTIONS
dc.subjectINFLUENZA
dc.subjectINHIBITION
dc.subjectINJECTING DRUG USERS
dc.subjectINSTITUTIONAL CAPACITY
dc.subjectINTERNATIONAL AIDS VACCINE INITIATIVE
dc.subjectINTERVENTION
dc.subjectLAWS
dc.subjectLEADERSHIP
dc.subjectLEARNING
dc.subjectLEARNING ACHIEVEMENT
dc.subjectMALE CLIENTS
dc.subjectMEASLES
dc.subjectMEDICAL RESEARCH
dc.subjectMOTHERS
dc.subjectNATIONAL AIDS CONTROL
dc.subjectNEONATAL TETANUS
dc.subjectNONGOVERNMENTAL ORGANIZATIONS
dc.subjectPARTNERSHIP
dc.subjectPATIENTS
dc.subjectPOLIO
dc.subjectPOLIO ERADICATION
dc.subjectPREGNANCY
dc.subjectPREGNANT WOMEN
dc.subjectPREVENTION EFFORTS
dc.subjectPREVENTION INTERVENTIONS
dc.subjectPREVENTIVE BEHAVIORS
dc.subjectPRIMARY HEALTH CARE
dc.subjectPRIMARY SCHOOL
dc.subjectPRIVATE SECTOR
dc.subjectPUBLIC HEALTH
dc.subjectPUBLIC SECTOR
dc.subjectPUBLIC SECTOR CLINICS
dc.subjectPUBLIC SERVICES
dc.subjectQUALITY ASSURANCE
dc.subjectREPRODUCTIVE AGE
dc.subjectRISK GROUPS
dc.subjectRISKY SEXUAL BEHAVIOR
dc.subjectRURAL AREAS
dc.subjectSCHOOLS
dc.subjectSEX WITH MEN
dc.subjectSEX WORKERS
dc.subjectSEXUALLY ACTIVE
dc.subjectSOCIAL MARKETING
dc.subjectSOCIAL SERVICES
dc.subjectSTDS
dc.subjectSTIS
dc.subjectSURVEILLANCE DATA
dc.subjectTARGET POPULATIONS
dc.subjectTECHNOLOGICAL ADVANCES
dc.subjectTETANUS
dc.subjectUSE OF CONDOMS
dc.subjectVACCINATION
dc.subjectVACCINE PREVENTABLE DISEASES
dc.subjectVACCINES
dc.subjectVULNERABLE GROUPS
dc.subjectYOUTH
dc.subjectFUNDING
dc.subjectACCESS TO EDUCATION
dc.titleThe Potential Demand for and Strategic Use of an HIV-1 Vaccine in Southern India

Archivos

Colecciones

AgroKnow